

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/799,299	03/12/2004	Gerald Horn	114309-1017	7833
75	7590 06/22/2006		EXAMINER	
BELL, BOYD & LLOYD LLC			HAND, MELANIE JO	
P.O. Box 1135 Chicago, 1L 60690-1135			ART UNIT	PAPER NUMBER
			3761	
			DATE MAIL ED: 06/22/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/799,299	HORN, GERALD			
Office Action Summary	Examiner	Art Unit			
	Melanie J. Hand	3761			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
 1) Responsive to communication(s) filed on 27 December 22 December 27 December 27 December 27 December 28 December 27 December 29 December 20 December 29 December 20 December 20	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
 4) Claim(s) 19-27 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 19-27 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. 					
Application Papers					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine	epted or b) objected to by the fidenaming(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). rected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date <u>various(3)</u> .	4) Interview Summary Paper No(s)/Mail Do 5) Notice of Informal P 6) Other:				

DETAILED ACTION

Response to Arguments

Applicant's arguments, see Remarks, filed December 27, 2005, with respect to the documented submission of appropriate documents establishing priority under provisional applications 60/154,033 and 60/154,893 have been fully considered and are persuasive. Accordingly, priority under said provisional applications is granted to the instant application. Examiner acknowledges the receipt of an amendment to the specification filed March 12, 2004, indicating the claim for priority.

Terminal Disclaimer

The terminal disclaimer filed on August 26, 2005 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of U.S. Patent Nos. 6,291,498 or 6,420,407 or pending Application No. 09/854,414 has been reviewed and is accepted. The terminal disclaimer has been recorded.

Information Disclosure Statements

The information disclosure statements (IDS) submitted on, June 29, 2004, August 24, 2004 and December 27, 2005 were filed after the mailing date of the Application on March 12, 2004. The submissions are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 22 and 27 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. There is no clear and sufficient description or definition for the ophthalmic artificial tear solution set forth in claims 22 and 27.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 19-27 are rejected under 35 U.S.C. 102(b) as being anticipated by Gluchowski (U.S. Patent No. 5,252,595).

With respect to Claims 19,22,23,24,26,27: Gluchowski teaches a therapeutic ophthalmic solution for use in a mammalian eye comprising an imidazoline and saline (Col. 4, lines 3-8).

Imidazoline, being an alpha receptor blocker is capable thus of effecting a contraction of the pupil in dim light by one millimeter or more. (Col. 3, lines 39-41, Col. 4, lines 15-19)

With respect to Claim 20: Phentolamine is an imidazoline homolog, therefore Gluchowski teaches the use of phentolamine as an active agent.

With respect to Claims 21,25: Gluchowski teaches that the active agent is present in an amount between 0.0001-1% weight by volume solvent (g/cc). Gluchowski teaches a composition having 300 ml water, therefore the active agent is present in an amount between 0.3-3,000 mg/cc. (Col. 4, lines 20-25, Col. 12, lines 48-50)

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Melanie J. Hand whose telephone number is 571-272-6464. The examiner can normally be reached on Mon-Thurs 8:00-5:30, alternate Fridays 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Tatyana Zalukaeva can be reached on 571-272-1115. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit: 3761

Melanie J Hand Examiner Art Unit 3761

MJH

TATYANA ZALUKAEVA SUPERVISORY PRIMARY EXAMINER